BVT.13

• Description:

  BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386) . In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/bvt-13.html

• Purity:

  98.44

• Solubility:

  DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(O)C1=CC(OC2=NC=CC=N2)=CC=C1NC(C3=CC=C(Cl)C=C3Cl)=O

• Molecular Formula:

  C18H11Cl2N3O4

• Molecular Weight:

  404.20

• Precautions:

  H302

• References & Citations:

  [1]Ostberg T, et al. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects[J]. Journal of Biological Chemistry, 2004, 279 (39) : 41124-41130.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [756813-87-3]